Canadian molecular diagnostics firm GenePOC and Cardinal Health have reached an agreement allowing Cardinal to exclusively distribute GenePOC's portable, qPCR-based molecular diagnostics instrument, revogene, and related assays in the US. The revogene instrument, designed to run point-of-care tests, received clearance from the FDA earlier this month for use with the GenePOC GBS LB assay in the detection of group B streptococcus.